# US 2010/0166803 A1 · Eimeria vaccine for turkeys > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2010/0166803 A1 - Document ID: US20100166803A1 - Status: Published application - Kind: A1 - Application number: 12/616,341 - Filed: 2009-11-11 - Published: 2010-07-01 - Earliest claimed: 2008-11-13 - Assignees: Intervet Inc.; Intervet International B.V. - Inventors: Steve Hewart Fitz-Coy; Gamini Saman Kumara Withanage; Alexandria Louise McGowan; Stephanie M. Cook - Web page: https://patentgrep.com/patent/US20100166803A1 ## CPC - C12Q 1/6893: for protozoa - A61K 39/012: Coccidia antigens - C07K 14/455: Eimeria - A61K 2039/552: {Veterinary vaccine} - Y02A 40/70: in livestock or poultry - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention discloses a vaccine that provides protection to turkeys from coccidiosis, and methods of making and using the vaccine alone, or in combinations with other protective agents. In addition, the present invention discloses PCR primer sets that are useful in identifying the species of Eimeria in a biological sample. ## Claims ### Claim 1 A vaccine composition comprising E. meleagrimitis 2 and E. meleagrimitis 1. ### Claim 2 (depends on 1) The vaccine of claim 1 further comprising one or more additional Eimeria species selected from the group consisting of E. adenoeides, E. gallopavonis, E. dispersa, E. innocua, and E. subrotunda. ### Claim 3 (depends on 2) The vaccine of claim 2 wherein the additional Eimeria species is E. adenoeides. ### Claim 4 (depends on 3) The vaccine of claim 3 further comprising E. meleagridis. ### Claim 5 (depends on 3) The vaccine of claim 3 further comprising E. dispersa. ### Claim 6 (depends on 1) The vaccine of claim 1 further comprising a parasite from the coccidia genus selected from the group consisting of Isospora, Cystoisospora, and Cryptosporidium. ### Claim 7 (depends on 1) The vaccine of claim 1 wherein the E. meleagrimitis 2 is an unattenuated strain. ### Claim 8 (depends on 7) The vaccine of claim 7 wherein the E. meleagrimitis 1 is an unattenuated strain. ### Claim 9 (depends on 8) The vaccine of claim 8 that comprises from about 10 to about 1000 oocysts of each of E. meleagrimitis 2 and E. meleagrimitis 1. ### Claim 10 (depends on 1) The vaccine of claim 1 wherein the E. meleagrimitis 2 is an attenuated strain. ### Claim 11 (depends on 10) The vaccine of claim 10 wherein the E. meleagrimitis 1 is an attenuated strain. ### Claim 12 (depends on 11) The vaccine of claim 11 in which the quantity of oocysts is from about 100 to about 10,000 oocysts of each of E. meleagrimitis 2 and E. meleagrimitis 1. ### Claim 13 (depends on 1) The vaccine of claim 1 that comprises merozoites. ### Claim 14 A vaccine composition comprising a first strain of E. meleagrimitis 2 and a second strain of E. meleagrimitis 2; wherein the first strain and the second strain have an asynchronous prepatent period. ### Claim 15 (depends on 1) The vaccine of claim 1 further comprising one or more additional Eimeria species selected from the group consisting of E. meleagrimitis 1, E. adenoeides, E. gallopavonis, E. dispersa, E. meleagridis, E. innocua, and E. subrotunda. ### Claim 16 (depends on 1) A method of immunizing a turkey against coccidiosis comprising administering to the animal an immunologically effective amount of the vaccine of claim 1. ### Claim 17 (depends on 17) The method of claim 17 wherein the vaccine is administered in the drinking water of the turkey. ### Claim 18 (depends on 17) The method of claim 17 wherein the vaccine is administered in the food of the turkey. ### Claim 19 A method of immunizing a turkey against coccidiosis comprising administering to the turkey a vaccine against E. meleagrimitis 2 comprising an immunologically effective amount E. meleagrimitis 2. ### Claim 20 (depends on 19) The method of claim 19 further comprising administering to the turkey one or more additional vaccines against a species of Eimeria other than E. meleagrimitis 2, wherein each additional vaccine comprises an immunologically effective amount of one or more Eimeria species selected from the group consisting of E. adenoeides, E. gallopavonis, E. dispersa, E. meleagridis, E. innocua, and E. subrotunda; wherein the administration of the vaccine against E. meleagrimitis 2 and the administration of one or more additional vaccines against a species of Eimeria other than E. meleagrimitis 2 can be performed in any order, including simultaneously in a combined administration. ### Claim 21 A method of identifying an Eimeria isolate as an E. meleagrimitis 2 comprising comparing the nucleotide sequence of the ITS-1 region of the genome of the Eimeria isolate with the nucleotide sequence of the ITS-1 region within SEQ ID NO: 44; wherein the Eimeria isolate is identified as an E. meleagrimitis 2 when the entire nucleotide sequence of the ITS-1 region of the genome of the Eimeria isolate exhibits greater then 87% homology with the entire nucleotide sequence of the ITS-1 region within SEQ ID NO: 44. ### Claim 22 A method of identifying an Eimeria isolate as an E. meleagrimitis 2 comprising comparing the nucleic acid sequence of the ITS-1 region of the genome of the Eimeria isolate with the nucleic acid sequence of the ITS-1 region within a nucleotide sequence selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, and SEQ ID NO: 34; wherein the Eimeria isolate is identified as an E. meleagrimitis 2 when the entire nucleic acid sequence of the ITS-1 region of the genome of the Eimeria isolate exhibits greater then 95% homology with the entire nucleic acid sequence of the ITS-1 region within said nucleotide sequence. ### Claim 23 A method of identifying an Eimeria isolate as an E. meleagrimitis 2 comprising comparing the nucleic acid sequence of the ITS-1 region of the genome of the Eimeria isolate with the entire nucleotide sequence of the ITS-1 region of SEQ ID NO: 44; wherein the Eimeria isolate is identified as an E. meleagrimitis 2 when the entire nucleotide sequence of the ITS-1 region of the genome of the Eimeria isolate exhibits 100% identity with the entire nucleotide sequence of the ITS-1 region within SEQ ID NO: 44. ### Claim 24 A polymerase chain reaction (PCR) primer pair for amplifying an ITS-1 region of the genome of a species of turkey Eimeria comprising a first and second primer, wherein the nucleotide sequences of the first and second primer respectively are selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, SEQ ID NO: 45 and SEQ ID NO: 46, SEQ ID NO: 47 and SEQ ID NO: 48, SEQ ID NO: 49 and SEQ ID NO: 50. ### Claim 25 (depends on 24) A PCR amplification kit comprising two or more PCR primer pairs of claim 24. ### Claim 26 (depends on 25) The kit of claim 25 wherein for one PCR primer pair the respective nucleotide sequences of the first and second primer comprise SEQ ID NO: 3 and SEQ ID NO: 4, and wherein for another PCR primer pair the respective nucleotide sequences of the first and second primer comprise SEQ ID NO: 11 and SEQ ID NO: 12. ### Claim 27 (depends on 26) The kit of claim 26 further comprising PCR primer pairs that comprise respective nucleotide sequences of the first and second primers of SEQ ID NO: 5 and SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, and SEQ ID NO: 9 and SEQ ID NO: 10. ### Claim 28 (depends on 26) The kit of claim 26 further comprising PCR primer pairs that comprise respective nucleotide sequences of the first and second primers of SEQ ID NO: 45 and SEQ ID NO: 46, SEQ ID NO: 47 and SEQ ID NO: 48, and SEQ ID NO: 49 and SEQ ID NO: 50. ### Claim 29 A PCR amplification kit specific for E. meleagrimitis 2 comprising a first primer and second primer, wherein the nucleotide sequence of the first primer comprises SEQ ID NO: 11 and the nucleotide sequence of the second primer comprises SEQ ID NO: 12 ### Claim 30 (depends on 27) A method of identifying E. meleagrimitis 2 in a biological sample comprising: (a) accessing nucleic acids contained by a biological sample; (b) amplifying the accessed nucleic acids by PCR in the presence of the primers from the PCR amplification kit of claim 27 under conditions that will produce a PCR product when nucleic acids from E. meleagrimitis 2 are contained by the biological sample; and (c) monitoring for the PCR product; wherein when the PCR product is detected during the monitoring, E. meleagrimitis 2 is identified as being in the biological sample. ### Claim 31 (depends on 28) A method of identifying pathogenic turkey Eimeria present in a biological sample comprising: (a) accessing nucleic acids contained by a biological sample; (b) amplifying the accessed nucleic acids by PCR in the presence of the primers from the PCR amplification kit of claim 28 under conditions that will produce a PCR product when nucleic acids from pathogenic turkey Eimeria are contained by the biological sample; and (c) monitoring for the PCR product; wherein when the PCR product is detected during the monitoring, pathogenic turkey Eimeria are identified as being in the biological sample. ### Claim 32 (depends on 28) A method of identifying the species of pathogenic turkey Eimeria present in a biological sample comprising: (a) accessing nucleic acids contained by a biological sample; (b) amplifying the accessed nucleic acids by PCR in the presence of the primers from the PCR amplification kit of claim 28 under conditions that will produce a PCR product when nucleic acids from pathogenic turkey Eimeria are contained by the biological sample; (c) detecting the PCR product; and (d) determining the species of the pathogenic turkey Eimeria associated with the detected PCR product; wherein said determining identifies the species of pathogenic turkey Eimeria present in the biological sample. ### Claim 33 (depends on 32) The method of claim 32 further comprising isolating one or more turkey Eimeria isolates from the biological sample and ascertaining one or more properties of the pathogenic turkey Eimeria isolated, wherein said properties are selected from the group consisting of its pathology, its pathogenicity, its cross-immunity, and its morphometrics.